26.32
Beam Therapeutics Inc Aktie (BEAM) Neueste Nachrichten
Technical analysis overview for Beam Therapeutics Inc. stock2025 Trading Recap & Low Risk High Reward Ideas - newser.com
Beam Therapeutics Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Beam Therapeutics (BEAM): Assessing Valuation After Fresh Buy Ratings, Clinical Updates, and Institutional Moves - Yahoo Finance
Jim Cramer on Beam Therapeutics: “That’s the Speculative Bottom There” - MSN
Beam Therapeutics (NASDAQ:BEAM) Earns "Buy" Rating from HC Wainwright - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat
Does Beam Therapeutics Inc. qualify in momentum factor screeningJuly 2025 Macro Moves & Long-Term Growth Portfolio Plans - newser.com
Bristol Myers Squibb buys Cambridge biotech for $1.5B - The Business Journals
HC Wainwright & Co. Reiterates Beam Therapeutics (BEAM) Buy Recommendation - Nasdaq
HC Wainwright & Co. Reiterates Buy Rating for BEAM at $80 Target - GuruFocus
What the charts say about Beam Therapeutics Inc. today2025 Price Targets & Community Consensus Picks - newser.com
Beam Therapeutics (NASDAQ:BEAM) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Beam Therapeutics Stock Soars 7.44%, Hits Intraday High of $27.55 - Markets Mojo
Jefferies initiates Beam Therapeutics stock with Buy rating on upcoming catalysts By Investing.com - Investing.com Canada
Jefferies initiates Beam Therapeutics stock with Buy rating on upcoming catalysts - Investing.com Canada
Jefferies Initiates Beam Therapeutics with "Buy" Rating, Eyeing Promising Gene-Editing Pipeline and Upcoming Catalysts - FinancialContent
Jefferies Initiates Beam Therapeutics at Buy Rating, $41 Price Target - MarketScreener
Does Beam Therapeutics Inc. show high probability of reboundEntry Point & Step-by-Step Swing Trade Plans - newser.com
SteelPeak Wealth LLC Invests $391,000 in Beam Therapeutics Inc. $BEAM - MarketBeat
Sector ETF performance correlation with Beam Therapeutics Inc.Product Launch & Low Risk Investment Opportunities - newser.com
Is Beam Therapeutics Inc. stock entering bullish territoryPortfolio Update Summary & Real-Time Volume Analysis - newser.com
Why Intellia Therapeutics’ Stock Could Be a Gene‑Editing Goldmine in 2025 – Deep Dive into NTLA’s Prospects - ts2.tech
Jim Cramer Sees More Upside For Shopify, Likes CoreWeave's AI Moves - Benzinga
Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences - FinancialContent
What Does Wall Street Think About Beam Therapeutics (BEAM)? - Yahoo Finance
Using Ichimoku Cloud for Beam Therapeutics Inc. technicalsQuarterly Profit Summary & Low Risk Entry Point Tips - newser.com
Recent Insider Transactions at Beam Therapeutics - TradingView
Beam Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Beam Therapeutics Shows Rising Price Performance With Jump To 81 RS Rating - MSN
Beam Therapeutics Inc Stock Analysis and ForecastGlobal Market Influence & Budget Friendly Capital Growth - earlytimes.in
What analysts say about Beam Therapeutics Inc stockRelative Strength Index (RSI) & Master Timing Market Moves - earlytimes.in
Is Beam Therapeutics Inc. (BEAM) the Best Emerging Technology Stock to Buy Now? - MSN
H.C. Wainwright Maintains Buy on Beam (BEAM), $80 Target on Pipeline Momentum - MSN
Is Beam Therapeutics Inc a good long term investmentGrowth vs. Value Investing & Affordable Investment Portfolio - earlytimes.in
Beam Therapeutics Inc. (BEAM) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Voya Investment Management LLC Has $686,000 Holdings in Beam Therapeutics Inc. $BEAM - MarketBeat
Peregrine Investment Management Inc. Increases Stock Holdings in Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics Hits Day High with 7.66% Surge in Stock Price - Markets Mojo
Beam Therapeutics (NASDAQ:BEAM) Shares Up 6.2%Time to Buy? - MarketBeat
Rhumbline Advisers Has $2.76 Million Stake in Beam Therapeutics Inc. $BEAM - MarketBeat
HC Wainwright Reiterates Buy Rating for Beam Therapeutics (NASDAQ:BEAM) - MarketBeat
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):